Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the USA / NCT06690099
Active, not recruiting Observational

Prospective Collection of Whole Blood Specimens From RhD Negative Pregnant Women

NCT06690099 · tracked via the Priya Life Science USA tracker
Sponsor
Devyser Inc
Phase
Observational
Started
2025-04-07
Last updated
2026-08-21

Condition(s) studied

Rhesus D GenotypePregnancy

Study summary

The purpose of this research is to collect blood samples and data from pregnant women who are Rh negative. The blood will be used for the future research and the development of non-invasive prenatal tests to identify Rh blood type status of the baby during pregnancy.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Willing and able to provide written informed consent 2. 18 years of age or older at enrollment 3. Women with a viable pregnancy (with documented fetal heartbeat) between 12 weeks, 0 days and 28 weeks, 0 days gestational age 4. Women with RhD negative antigen status by serology 5. Willing to provide neonatal ABO and RhD genotyping status Exclusion Criteria: 1\. Women with multiple gestation pregnancy

Primary outcome measure(s)

  • Fetal RhD determination from maternal whole blood — 18 months
    Collected samples will be used for future development of non-invasive prenatal test to determine fetal RhD status from maternal whole blood

Trial sites (1)

FacilityCityRegionStatus
Ochsner Health New Orleans Louisiana

More Devyser Inc. trials in the USA

A Multicenter, Prospective Blood Collection Study in a Kidney Transplant Population Recruiting

Other trials for the same condition

Avalglucosidase Alfa Pregnancy Study Recruiting
A Study to Assess the Pregnancy Outcome in Women Exposed to Dayvigo® During Pregnancy Compared to an Unexposed Control Population Active, not recruiting
Kesimpta (Ofatumumab) Pregnancy Registry Recruiting
A Study to Evaluate Safety of Exposure to Wegovy During Pregnancy Enrolling by invitation
Bempedoic Acid Pregnancy Surveillance Program Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06690099 on ClinicalTrials.gov ↗ ← All trials in the USA